Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
EMRA-MED Arzneimittel is a leading German pharmaceutical company specializing in the parallel import and re-import of original brand-name medications within the European Union. Established in 1984 and headquartered in Trittau, the company sources pharmaceuticals from EU member states where prices are lower and distributes them to pharmacies and wholesalers in the German market. This business model provides significant cost savings for the German healthcare system, including statutory health insurance funds and patients. EMRA-MED's extensive product range includes high-cost specialty medicines for chronic and complex conditions such as cancer, autoimmune diseases, and HIV. As a subsidiary of the PHOENIX Group, the company benefits from a robust European distribution network and adheres to strict Good Manufacturing Practice (GMP) standards for repackaging and labeling. The company is recognized as one of the pioneers in the German re-import sector, maintaining a focus on quality and supply chain integrity.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on EMRA-MED Arzneimittel.